Home › Funds › Avoro Capital Advisors LLC › CYTK
Avoro Capital Advisors LLC position in CYTK
CYTOKINETICS INC · Health Care
Avoro Capital Advisors LLC reported holding 4,900,000 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$323.0M, representing 3.34% of its reported portfolio and ranking #9 among its reported holdings. Avoro Capital Advisors LLC has disclosed CYTK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's CYTK position evolved
Avoro Capital Advisors LLC first disclosed a stake in CYTK in Q1 2026 at 3,333,333 shares (US$219.7M). The position peaked in Q2 2026 at 4,999,999 shares, worth US$425.9M. Across 3 filings, Avoro Capital Advisors LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,900,000 shares valued at US$323.0M — a reduction of -99,999 shares quarter over quarter.. Notable position changes include a 50% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 3.33M | $219.70M | New |
| Q2 2026 | 5.00M | $425.95M | Add |
| Q3 2026 | 4.90M | $322.96M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 39 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Polar Capital Holdings Plc (US$227.7M), RTW INVESTMENTS, LP (US$188.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Polar Capital Holdings Plc 9.64M sh · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M sh · $188.63M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.18M sh · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M sh · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Melqart Asset Management (UK) Ltd 761.54K sh · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held CYTK?
Avoro Capital Advisors LLC has disclosed CYTK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Avoro Capital Advisors LLC's current position in CYTK?
As of Q3 2026, Avoro Capital Advisors LLC holds 4.90M shares of CYTK (CYTOKINETICS INC), valued at $322.96M, representing 3.34% of its reported portfolio and ranking #9.
Has Avoro Capital Advisors LLC been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in CYTK. The position peaked in Q2 2026 at 5.00M shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Polar Capital Holdings Plc, RTW INVESTMENTS, LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.